.png){kind=icon}
返回
Massive Unsourced Random Access: Exploiting Angular Domain Sparsity
.png){kind=icon}
OA
AI
DOI：10.1109/TCOMM.2022.3153957.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
This paper investigates the unsourced random access (URA) scheme to accommodate numerous machine-type users communicating to a base station equipped with multiple antennas. Existing works adopt a slotted transmission strategy to reduce system complexity; they operate under the framework of coupled compressed sensing (CCS) which concatenates an outer tree code to an inner compressed sensing code for slot-wise message stitching. We suggest that by exploiting the MIMO channel information in the angular domain, redundancies required by the tree encoder/decoder in CCS can be removed to improve spectral efficiency, thereby an uncoupled transmission protocol is devised. To perform activity detection and channel estimation, we propose an expectation-maximization-aided generalized approximate message passing algorithm with a Markov random field support structure, which captures the inherent clustered sparsity structure of the angular domain channel. Then, message reconstruction in the form of a clustering decoder is performed by recognizing slot-distributed channels of each active user based on similarity. We put forward the slot-balanced K-means algorithm as the kernel of the clustering decoder, resolving constraints and collisions specific to the application scene. Extensive simulations reveal that the proposed scheme achieves a better error performance at high spectral efficiency compared to the CCS-based URA schemes.
Keyword:
Activity detection
channel estimation
compressed sensing
massive machine-type communications
random access
期刊
IF:
8.3
论文数:
1.2W
被引数:
3.6W
机构
引用论文
Generalized Approximate Message Passing for Massive MIMO mmWave Channel Estimation With Laplacian Prior基于拉普拉斯先验的大规模MIMO毫米波信道估计的广义近似消息传递
OAAI
OAAI分享收藏Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib.png)
Blood
BloodIF0
PREAI
分享收藏trans-Diiodopentakis(tetrahydrofuran)ytterbium(III) tetraiodo-trans-bis(tetrahydrofuran)ytterbium(III) 反式 -二碘伏 (四氢呋喃) 镱 (III) 四碘伏- 反式 -二 (四氢呋喃) 镱 (III)
PREAI
分享收藏
查看更多内容